Stock comparison
IDEXX Laboratories
Teva Pharmaceutical Industries Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
TEVA
Teva Pharmaceutical Industries Limited
Market cap
$39.67B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | TEVA | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 46D | IDXX |
| Benjamin Graham | 80A | 60D | IDXX |
| Philip Fisher | 75B | 59C | IDXX |
| Peter Lynch | 71B | 53C | IDXX |
| Joel Greenblatt | 83C | 49D | IDXX |
| Charlie Munger | 87A | 50D | IDXX |
| Terry Smith | 84A | 41D | IDXX |
Side-by-side metrics
| Metric | IDXX | TEVA |
|---|---|---|
| Market cap | $44.12B | $39.67B |
| P/E (TTM) | 39.0x | 25.4x |
| EV/EBIT | 31.6x | 24.8x |
| ROIC (TTM) | 40.66% | 11.49% |
| Gross margin | 62.05% | 51.98% |
| Net margin | 24.63% | 9.03% |
| Revenue CAGR 5y | 7.56% | 2.1% |
| EPS CAGR 5y | 10.79% | 34.13% |
| Debt / Equity | 0.7x | 2.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Revenue CAGR 5y7.56%vs 2.1%+72%
- ROIC (TTM)40.66%vs 11.49%+72%
- Debt / Equity0.7xvs 2.1x+66%
- Net margin24.63%vs 9.03%+63%
TEVA leads on
- EPS CAGR 5y34.13%vs 10.79%+68%
- P/E (TTM)25.4xvs 39.0x+35%
- EV/EBIT24.8xvs 31.6x+21%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.